CABERNOVA
CABERNOVA Tablet by NovaTech Sciences contains Cabergoline (CAS 81409‑90‑7). Trusted manufacturer, supplier, and exporter of pharmaceutical‑grade dopamine agonist for prolactin regulation and hormone support.
CAS Number: 81409-90-7
CABERNOVA (Cabergoline 0.5 mg) helps regulate high prolactin levels caused by anabolic steroid use or hormonal imbalances. It supports hormonal stability, prevents prolactin-related side effects such as mood changes, water retention, and decreased libido, and enhances post-cycle therapy (PCT) results. Widely used by bodybuilders, athletes, and fitness enthusiasts, CABERNOVA helps maintain optimal hormone health and improves overall cycle performance.
CABERNOVA by Nova Techsciences is a tablet formulation containing Cabergoline 0.5 mg. Cabergoline is an ergot-derived dopamine D2 receptor agonist and prolactin inhibitor identified by CAS Number 81409-90-7. In authorised clinical settings, cabergoline is used for conditions associated with elevated prolactin levels. Treatment decisions should always follow local prescribing information and an assessment by a qualified healthcare professional.
CABERNOVA Product Overview
Important product information includes:
- Product name: CABERNOVA
- Active compound: Cabergoline
- Strength: 0.5 mg per tablet
- Dosage form: Oral tablet
- CAS Number: 81409-90-7
- Brand: Nova Techsciences
The website description, packaging and technical records should consistently state the complete formulation, excipients, tablet count, batch number, manufacturing date, expiry date and approved storage conditions. Any therapeutic claim should match the product’s authorised status in the country where it is supplied.
Quality, Documentation and Traceability
A reliable CABERNOVA product profile should be supported by documented quality controls. Relevant records can include raw-material identification, active-ingredient assay, content-uniformity testing, dissolution, impurity assessment, microbiological quality and packaging-integrity checks. Each batch should carry a unique number connected to its manufacturing and laboratory-release records.
For the United Kingdom, Netherlands and other European markets, Nova Techsciences should clearly communicate the medicine’s marketing-authorisation status, prescription category, responsible manufacturer and adverse-event reporting route. Claims concerning purity or pharmaceutical quality should only be used when current supporting evidence is available.
Safety and Responsible Use
Cabergoline can cause effects such as nausea, dizziness, headache, tiredness and low blood pressure. More serious concerns may include heart-valve or fibrotic disorders, particularly in circumstances requiring longer-term treatment. Appropriate cardiovascular assessment and clinical monitoring may therefore be necessary under authorised prescribing guidance.
CABERNOVA should not be used for self-medication, unsupervised hormone management, bodybuilding or post-cycle treatment. Patients should tell their prescriber about cardiovascular conditions, uncontrolled hypertension, pregnancy, breastfeeding and all medicines they use. Interaction checks are important because dopamine-antagonist medicines and certain other treatments may affect cabergoline therapy.
Related Nova Techsciences Products
CLOMINOVA
CLOMINOVA contains Clomiphene Citrate, identified by CAS Number 50-41-9. It is a separate prescription compound associated with medically supervised reproductive treatment. Its contraindications, possible visual side effects, liver-related precautions and country-specific authorisation status should be reviewed independently.
ENCLOMINOVA
ENCLOMINOVA is presented as Enclomiphene Citrate 25 mg, with CAS Number 7599-79-3. It is chemically related to clomiphene but requires its own regulatory assessment, verified indication, quality documentation and safety information rather than being treated as automatically interchangeable.
FEMANOVA
FEMANOVA contains Letrozole 2.5 mg, an aromatase inhibitor identified by CAS Number 112809-51-5. Letrozole has distinct authorised uses and safety considerations, including pregnancy-related restrictions, and should only be described through current approved prescribing information.
HALONOVA
HALONOVA contains Fluoxymesterone 5 mg, with CAS Number 76-43-7. It is an anabolic-androgenic prescription medicine with important liver, cardiovascular and hormonal risks. Its page should include prominent contraindications, monitoring requirements and warnings against non-medical or performance-enhancing use.
NOVA-T3
NOVA-T3 is presented within the Nova Techsciences thyroid-hormone product range and is associated with Liothyronine Sodium, CAS Number 55-06-1. Thyroid-hormone products require precise strength identification, medical monitoring and clear warnings against unsupervised weight-loss or performance use.
CABERNOVA should ultimately be presented through accurate chemical identification, balanced safety information, transparent batch documentation and clearly stated regulatory status. This approach supports a more credible product page for healthcare professionals, distributors and regulatory reviewers.
Important Information & FAQs
Precautions & Contraindications
Precautions
- Always use CABERNOVA under professional guidance.
- Follow prescribed dosage; avoid self-medication.
- Inform your doctor of all medications, supplements, or steroid compounds.
- Avoid alcohol or recreational substances as they may interfere with dopamine activity.
- Keep out of reach of children; store in a cool, dry place.
- Seek medical attention for chest pain, severe headache, vision changes, or unusual symptoms.
- Pregnant or breastfeeding women should avoid CABERNOVA unless approved by a medical professional.
Contraindications
- Do not use if allergic to Cabergoline or other ergot derivatives.
- Avoid if you have uncontrolled hypertension, heart valve disorders, or serious cardiovascular conditions.
- Discontinue and seek medical help if severe or unusual symptoms occur.
- Use only under medical supervision during steroid cycles or PCT.
Related Products
AROMANOVA
High-potency Exemestane tablets for advanced estrogen control and PCT support.
CLOMINOVA
Clomiphene Citrate 50 mg tablets for post-cycle therapy, testosterone recovery, and hormonal balance.
ENCLOMINOVA
Premium Enclomiphene Citrate tablets for testosterone boosting, PCT recovery, and hormonal balance.
FEMANOVA
High-purity aromatase inhibitor for reliable estrogen control.